The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
 
Shintaro Nakano
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Japan Agency for Medical Research and Development
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kazuaki Harada
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Shinya Kajiura
No Relationships to Disclose
 
Yasuo Takahashi
No Relationships to Disclose
 
Hidenori Karasaki
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Yasushi Tsuji
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Medicon; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takahide Sasaki
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Tomoe Kobayashi
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Chugai Pharma; Daiichi Sankyo; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Shiseido; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; Daiichi Sankyo; Eisai; Incyte; IQvia; Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha